CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.
CMS is trying to make a 2-sided risk model in the Oncology Care Model enticing for practices, but there is still a lot of math practices need to work out before making the decision, said Blase Polite, MD, associate professor of medicine and the executive director for accountable care at the University of Chicago.
Transcript
Will the adjustments CMS has made for practices to take on 2-sided risk in the Oncology Care Model make a difference?
I think they are clearly trying to do everything possible to entice practices in and there have been very nice moves. I think there are more practices considering 2-sided risk than I would have predicted 2 or 3 years ago. So, I do think that they’re going to get a larger number than, again, I think they would have expected.
They’re trying to be as accommodating as possible because I know from their standpoint, having people who are interested in a 2-sided risk model is very, very important for them to be able to show that this is a feasible model going forward. So, they seem to be bending over backwards to get people enticed into the 2-sided risk model.
Our institute and others around the country are still running the numbers, there’s still al ittle bit of confusion of exactly how the math works out in the model, and what’s included in there. But, I think as people start running the numbers, to the extent that people will get the 5% bonus, the [Merit-based Incentive Payment System] bonus from being an advanced practice [alternative payment model], I think all those things make it more and more enticing to do a 2-sided risk model.
Now, on the other hand, there are those who do say, “Should we be rewarding CMS for a model that many consider flawed? And if by going into 2-sided risk, are we essentially voting with our approval, by doing 2-sided risk, that we’re happy with the model?” So, I know there is tension in the community on that side.
But they clearly are doing everything they can to get us into a 2-sided risk model.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More